1.
National Institute for Clinical Excellence: Guidance on the Use of Trastuzumab for the Treatment of Advanced Breast Cancer (TA34). London, National Institute for Clinical Excellence, 2002.
2.
National Institute for Health and Clinical Excellence: Advanced Breast Cancer: Diagnosis and Treatment (CG81). London, National Institute for Health and Clinical Excellence, 2009.
3.
Extra J-M, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, et al: Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 2010;15:799-809.
4.
Von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 2009;27:1999-2006.
5.
Waddell T, Kotsori A, Constantinidou A, Yousaf N, Ashley S, Parton M, et al: Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience. Br J Cancer 2011;104:1675-1679.
6.
Wong Y-N, Ottesen RA, Hughes ME, Niland JC, Theriault R, Edge SB, et al: Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence? Oncologist 2011;16:559-565.
7.
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-1791.
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or...
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.